In a 79-year-old male with coronary artery disease and heart failure with preserved ejection fraction, diabetes mellitus, hypertension, trace bilateral peripheral edema, normal vital signs, normal ECG, and currently taking aspirin, atorvastatin (Lipitor), and metformin, who is scheduled for left hip replacement, what additional pre‑operative studies are indicated for clearance?

Pre-Operative Studies for Hip Replacement in High-Risk Cardiac Patient

Based on current ACC/AHA guidelines, this patient requires reassessment of left ventricular function with echocardiography given his 2-year-old echo and trace bilateral edema suggesting possible HF decompensation, but does NOT require routine stress testing given his stable clinical status. 1, 2

Risk Stratification

This 79-year-old patient undergoing hip replacement (intermediate-risk surgery) has multiple cardiac risk factors:

• Known coronary artery disease
• Heart failure with preserved ejection fraction (HFpEF)
• Diabetes mellitus (A1c 7.2%)
• Age >65 years
• Trace bilateral edema (potential volume status change)

Hip replacement is classified as intermediate-risk surgery (1-5% risk of major adverse cardiac events), placing him at elevated perioperative risk based on the Revised Cardiac Risk Index 1, 2.

Required Pre-Operative Testing

1. Echocardiography - INDICATED

It is reasonable to obtain a repeat echocardiogram given:

• Last echo was 2 years ago (>1 year interval) 2
• New finding of trace bilateral edema suggesting possible clinical status change 1, 2
• Known HFpEF with potential worsening dyspnea or volume status

The 2014 ACC/AHA guidelines state: "It is reasonable for patients with HF with worsening dyspnea or other change in clinical status to undergo preoperative evaluation of LV function" (Class IIa, Level C) 1, 2. While the edema is only trace, reassessment of LV function in clinically stable patients with previously documented dysfunction "may be considered" if there has been no assessment within a year (Class IIb, Level C) 2.

2. 12-Lead ECG - Already Completed

The patient already has a normal ECG, which satisfies the Class IIa recommendation for patients with known coronary heart disease or significant structural heart disease undergoing intermediate-risk surgery 1, 2.

3. Basic Laboratory Studies - INDICATED

Standard pre-operative labs should include:

• Complete blood count (hemoglobin/hematocrit for surgical planning)
• Basic metabolic panel (renal function given diabetes and potential HF)
• Hemoglobin A1c (already done at 7.2% - acceptable)

These are standard for intermediate-risk surgery in patients with diabetes and cardiovascular disease 3.

Testing NOT Indicated

Stress Testing - NOT RECOMMENDED

Routine stress testing is NOT indicated for this patient despite his elevated risk profile because:

1. He has stable symptoms - No mention of unstable angina, recent chest pain, or acute coronary syndrome 1, 2

2. Normal vital signs and ECG - Suggests clinical stability

3. Functional capacity appears adequate - He is ambulatory enough to require hip replacement (suggests >4 METs functional capacity) 1, 2, 4

4. Testing would not change management - The 2014 ACC/AHA guidelines explicitly state: "If testing will not impact decision making or care, then proceed to surgery according to guideline-directed medical therapy" (Step 7) 1, 2, 4

The guidelines reserve stress testing for patients with:

• Poor (<4 METs) or unknown functional capacity AND
• Elevated risk AND
• When results would change management (e.g., willingness to undergo revascularization) 1, 2

Key caveat: If during pre-operative assessment the patient reports poor functional capacity (cannot climb 2 flights of stairs or walk 4 blocks), then pharmacological stress testing "may be considered" (Class IIb) if it would change management 1, 2. However, given he is presenting for hip replacement, his functional limitation is likely orthopedic rather than cardiac.

Coronary Angiography - NOT RECOMMENDED

"Routine preoperative coronary angiography is not recommended" (Class III: No Benefit, Level C) 1, 2. This would only be considered if stress testing revealed high-risk features (left main disease, severe multivessel disease with reduced EF), which is not applicable here.

Medication Optimization

Continue current guideline-directed medical therapy:

• Aspirin - Continue perioperatively (discuss with surgeon regarding timing)
• Atorvastatin (Lipitor) - Continue perioperatively 5
• Metformin - Hold on day of surgery per standard protocol
• Cozaar (losartan) - Continue, though may hold morning of surgery depending on institutional protocol

Ensure beta-blocker therapy is considered if not already prescribed, given CAD and HFpEF 1.

Clinical Pitfalls to Avoid

1. Do not delay surgery for extensive cardiac testing in stable patients - this increases morbidity without proven benefit 1, 2

2. Do not order stress tests reflexively in high-risk patients - the 2014 guidelines moved away from routine testing toward functional capacity assessment 1, 2

3. Do not ignore the trace edema - this warrants echo reassessment to ensure HFpEF is compensated 1, 2

4. Do not stop statins perioperatively - continue through surgery 5

Summary of Additional Studies Needed

✓ Echocardiography (to reassess LV function given 2-year interval and trace edema)
✓ Complete blood count
✓ Basic metabolic panel (renal function, electrolytes)
✗ Stress testing (not indicated - stable patient, adequate functional capacity)
✗ Coronary angiography (not indicated)
✗ Repeat ECG (already normal)